ArticleScientific reports2016
Phenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Leveraging AI and Natural Compounds: Innovative Approaches in the Diagnosis and Treatment of Hepatocellular Carcinoma.Current pharmaceutical design · 2026Review
- Metabolomics in the Prediction and Early Diagnosis of Type 2 Diabetes Mellitus: Advances and Applications.International journal of medical sciences · 2026Review
- Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.Frontiers in immunology · 2024Article
- Lipid metabolic profiling and diagnostic model development for hyperlipidemic acute pancreatitis.Frontiers in physiology · 2024Article
- Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians.Cancer cell international · 2023Review
- Review
- Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings.Diagnostics (Basel, Switzerland) · 2023Review
- Guide to Metabolomics Analysis: A Bioinformatics Workflow.Metabolites · 2022Review
- Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review.Translational gastroenterology and hepatology · 2022Review
- Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure.Bioengineered · 2021Article
- Optimizing the Properties of LaNanomaterials (Basel, Switzerland) · 2021Article
- Article
- Aging-related markers in rat urine revealed by dynamic metabolic profiling using machine learning.Aging · 2021Article
- Current applications of artificial intelligence combined with urine detection in disease diagnosis and treatment.Translational andrology and urology · 2021Review
- Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC).Cancer management and research · 2021Article
- Metabolic rearrangements in primary liver cancers: cause and consequences.Nature reviews. Gastroenterology & hepatology · 2019Review
- Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.World journal of gastroenterology · 2019Review
- Cancer metabolomic markers in urine: evidence, techniques and recommendations.Nature reviews. Urology · 2019Review
- Predicting overall survival of patients with hepatocellular carcinoma using a three-category method based on DNA methylation and machine learning.Journal of cellular and molecular medicine · 2019Article
- Urine Nuclear Magnetic Resonance (NMR) Metabolomics in Age-Related Macular Degeneration.Journal of proteome research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocarcinoma (HCC) is one of the deadliest cancers in the world and represents a significant disease burden. Better biomarkers are needed for early detection of HCC. Metabolomics was applied to urine samples obtained from HCC patients to discover noninvasive and reliable biomarkers for rapid diagnosis of HCC. Metabolic profiling was performed by LC-Q-TOF-MS in conjunction with multivariate data analysis, machine learning approaches, ingenuity pathway analysis and receiver-operating characteristic curves were used to select the metabolites which were used for the noninvasive diagnosis of HCC. Fifteen differential metabolites contributing to the complete separation of HCC patients from matched healthy controls were identified involving several key metabolic pathways. More importantly, five marker metabolites were effective for the diagnosis of human HCC, achieved a sensitivity of 96.5% and specificity of 83% respectively, could significantly increase the diagnostic performance of the metabolic biomarkers. Overall, these results illustrate the power of the metabolomics technology which has the potential as a non-invasive strategies and promising screening tool to evaluate the potential of the metabolites in the early diagnosis of HCC patients at high risk and provides new insight into pathophysiologic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.